PR99799

LISBON, Portugal March 20, 2023 /PRNewswire=KYODO JBN/

Hovione, the specialist integrated CDMO, leader in spray drying and particle

engineering, and Ripple Therapeutics, a leading ophthalmic sustained drug

delivery company, have entered a strategic partnership to expand the use of

Ripple's Epidel(R) platform beyond ophthalmic applications.

The core feature of Ripple's Epidel(R) technology is the ability to deliver

sustained-release pharmaceuticals with surface erosion release kinetics without

the use of polymers or excipients. This enables higher drug loading, smaller

size implants, defined and predictable biocompatible degradation products with

straightforward and scalable manufacturing processes. Surface erosion-based

drug release provides a highly effective way to control dose and duration. By

incorporating Ripple's Epidel(R) platform into its toolbox, Hovione can expand

its portfolio of novel drug delivery solutions to the pharmaceutical industry.

"The combination of technology synergy, innovative vision and cultural fit

makes collaborating with Hovione an exciting next step in the advancement of

the Epidel(R) platform beyond the ophthalmic field," stated Dr. Wendy Naimark,

Ripple co-founder and Chief Technology Officer. "Hovione's expertise in

controlled, sustained drug delivery, along with their experience in chemical

synthesis and pharmaceutical manufacturing, makes for a great partnership."

"We are thrilled to partner with Ripple, who developed a state-of-the-art

platform for sustained release," says Dr. Jean-Luc Herbeaux, Hovione's CEO. "

Our shared goal is to accelerate and broaden the access to this highly

innovative and enabling technology for the benefit of our pharmaceutical

customers and their patients worldwide."

By extending the use of the Epidel(R) platform beyond ocular applications, this

partnership will enable the development of a diverse range of new products with

optimal sustained release profiles.

About Hovione:

Hovione is an international company with over 60 years of experience in

pharmaceutical development and manufacturing operations. As a  Contract

Development and Manufacturing Organization (CDMO) with a fully integrated

offering of services for drug substances, drug product intermediates and drug

products. The company has four FDA inspected sites in the USA, Portugal,

Ireland and China and development laboratories in Lisbon, Portugal and New

Jersey, USA. Hovione provides pharmaceutical customers services for the

development and compliant manufacture of innovative drugs, including highly

potent compounds, and customized product solutions across the entire drug life

cycle. In the inhalation area, Hovione offers a complete range of services,

from API, formulation development and devices. Hovione's culture is based on

innovation, quality and dependability. Hovione was the first Chemical/

Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360,

EFCG and participates actively in industry quality improvement initiatives to

lead new global industry standards.

About Ripple Therapeutics:

Ripple Therapeutics Corporation is a clinical stage, privately held company

that is focused on ophthalmic therapeutics with controllable, sustainable drug

delivery. The core feature of Ripple's Epidel(TM) technology is the ability to

engineer sustained-release pharmaceuticals with surface erosion release

kinetics without the use of polymers or excipients. Ripple's novel therapeutics

provide for better outcomes for patients, easier management of care for

physicians and lower costs for payors. Ripple has a full product pipeline in

development. www.rippletherapeutics.com

For more information, please visit www.hovione.com or contact:

Vanessa Romeu | Communications Director | vromeu@hovione.com |Tel: +351 21 982

9000

Or visit www.rippletherapeutics.com

SOURCE: Hovione